Screening for hepatocellular carcinoma after HBsAg clearance age before cirrhosis?: Age before cirrhosis?

Journal of Clinical Gastroenterology

Volumn 45, Issue 1, 2011, Pages 4-5

  Lutchman, Glen A ^a   Nguyen, Mindie A ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; HEPATITIS B SURFACE ANTIGEN;

CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; COST; EDITORIAL; FAMILY HISTORY; FOLLOW UP; GOLD STANDARD; HEPATITIS B; HUMAN; LIVER BIOPSY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; UNIVARIATE ANALYSIS;

AGE FACTORS; CARCINOMA, HEPATOCELLULAR; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MASS SCREENING; RISK FACTORS; TIME FACTORS;

EID: 78650933760     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181faf0d1     Document Type: Editorial

References (14)

1. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 suppl 1): S5-S16.
2. Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009;16:453-463.
3. McMahon BJ, Holck P, Bulkow L, et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135:759-768.
4. Chang MH, Chen C, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336:1855-1859. (Pubitemid 27263972)
5. Chang MH, Shan WY, Chen CJ, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA. 2000;284:3040-3042.
6. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-1531.
7. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007;46:45-52.
8. Arase Y, Suzuki F, Suzuki Y, et al. Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance. Intervirology. 2007;50:161-165.
9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661-662.
10. Kim JH, Lee YS, Lee HJ, et al. HBsAg seroclearance in chronic hepatitis b: implications for hepatocellular carcinoma. J Clin Gastroenterol. 2011;45:64-68.
11. Tong MJ, Nguyen MO, Tong LT, et al. Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen. Clin Gastroenterol Hepatol. 2009;7:889-893.
12. Yuen MF, Wong D, Fung K, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135:1192-1199.
13. Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009;29:242-247.
14. Myers RP, Tainturier MH, Ratzui V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003;39:222-230.